株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

中国のアニマルヘルス企業:上位20社

Animal Pharm: China Top 20 Companies 2017

発行 Animal Pharm 商品コード 527406
出版日 ページ情報 英文 145 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=110.75円で換算しております。
Back to Top
中国のアニマルヘルス企業:上位20社 Animal Pharm: China Top 20 Companies 2017
出版日: 2017年03月01日 ページ情報: 英文 145 Pages
概要

当レポートでは、中国のアニマルヘルス (動物用医薬品) 企業について調査分析し、上位20社に焦点を当てて、市場の概要、動向と発展、市場機会と課題、業界規制など、体系的な情報を提供しています。

第1章 中国の経済と政治制度

  • 中国とその経済について
  • 経済発展
  • 政治の概要

第2章 農業、家畜、ペット

  • 中国の農業開発と政策
  • 畜産業
  • 家禽
  • 乳牛
  • 水産養殖
  • ペット

第3章 中国のアニマルヘルス市場の概要

  • 世界と中国のアニマルヘルス産業の比較
  • 中国とアニマルヘルス製品の国際貿易
  • 中国国内のアニマルヘルス産業
  • 動物用生物製剤の企業
  • 産業集中
  • 研究の概要
  • 動物用生物製剤の売上高の概要

第4章 強制ワクチン

  • 市場の概要
  • その他の動物用生物製剤
  • 動物用医薬品、従来の中国の動物用医薬品

第5章 経済の概要

  • 動物用医薬品の生産額
  • 動物用医薬品の売上高
  • 研究の概要
  • 動物用API企業
  • 産業集中

第6章 中国の動物用医薬品

第7章 輸出

  • API輸出

第8章 中国のアニマルヘルス上場企業 (上位13社) の概要

  • 概要
  • China Animal Husbandry Group
  • China Animal Husbandry Industry Corporation Ltd.
  • Jinyu Bio-Technology Co. Ltd. (Jinyu Baoling Biological Pharmaceutical)
  • Tianjin Ringpu Biotechnology Co. Ltd.
  • Xinjiang Tecon Animal Husbandry Bio-Technologu Co., Ltd (TECON)
  • Guangdong Wens Dahuanong Biotechnology Co. Ltd.
  • Shandong Lukang
  • Pulike Biological Engineering
  • Zhejiang Shenghua Biok Biology Co. Ltd. (Qingdao Yibang Bioengineering Co., Ltd)
  • Beijing Dabeinong Technology Group
  • China Animal Healthcare Ltd.
  • その他

第9章 国際的なアニマルヘルス主要企業

  • Zoetis
  • Merck/MSD Animal Health
  • Merial
  • Elanco
  • Bayer Animal Health China
  • Boehringer Ingelheim
  • IDEXX Laboratories
  • Virbac
  • Ceva Sante Animale
  • その他
目次
Product Code: 86760

The first of its kind published by Informa, the Animal Pharm China Top 20 Companies report explores the sector's rapid development and reveals how foreign firms are now well-placed to take advantage of opportunities.

Home to the world's largest livestock industry, China has been the object of much fascination among global animal health companies. This report provides an overview of China's current market and identifies trends and developments, market opportunities and challenges, and industry regulation in animal health.

With a CARGR of 11.4% between 2007 and 2015, China's animal health industry has grown faster than the rest of the collective global animal health industry and is undergoing rapid transformation. However, with domestic animal health companies suffering from serious shortcomings and the sector remaining highly fragmented, new routes to market exist for foreign firms. Large-scale meat processors and livestock producers want high-quality animal health products. Chinese state-run and private animal health enterprises court commercial partnerships; and veterinary universities, institutes and associations are approaching counterparts abroad to collaborate on bilateral research programmes and industry events.

Yet challenges for foreign firms still abound. While negotiating China's vast and complex regulatory frameworks is not straightforward, this report reveals how relationships have been successfully established.

Findings in the report include:

  • Top 20 domestic animal health companies in China
  • Top 10 international animal health companies in China
  • Sales of animal livestock vaccines in China
  • Sales of animal livestock veterinary medicines
  • Compulsory livestock vaccines and sales
  • Comprehensive livestock data
  • Pet ownership trends
  • Industry regulation - international perceptions and comparisons
  • Spending on research and development by Chinese animal health firms
  • Registered veterinary medicines (both APIs and manufactured medicines) and biologicals
  • Sales of traditional Chinese veterinary medicine
  • Chinese veterinary API manufacturing

Table of Contents

Contents

Executive Summary

Chapter 1: China's Economy & Political System

  • 1.1. Introduction to China and its economy
  • 1.2. Economic development
    • 1.2.1. Economic risks
    • 1.2.2. The state in the economy
    • 1.2.3. The state in the animal health sector
    • 1.2.4. Foreign direct investment in China
    • 1.2.5. US dollar peg
    • 1.2.6. Flaws in China's Statistical Data
  • 1.3. Political Overview
    • 1.3.1. China's political system
    • 1.3.2. Political Risks
    • 1.3.3. The Communist Party
    • 1.3.4. Centre vs Provinces
    • 1.3.5. China's regulatory and judiciary
    • 1.3.6. Corruption and Xi's anti-corruption campaign
    • 1.3.7. Food safety and environmental protection
    • 1.3.8. Key Indicators

Chapter 2: Agriculture, Livestock and Pets

  • 2.1. China's agriculture development and policy
  • 2.2. The livestock industry
  • 2.3. Pork
    • 2.3.1. Structural change
    • 2.3.2. Market volatility
    • 2.3.3. Long-term forecast
    • 2.3.4. Swine diseases
  • 2.4. Poultry
    • 2.4.1. Structure
    • 2.4.2. Tyson Foods
    • 2.4.3. Marfrig and Chinwhiz
    • 2.4.4. Cargill
    • 2.4.5. Brasil Foods (BRF) and Dah Chong Hong
    • 2.4.6. Perdue Farms and Dah Chong Hong
    • 2.4.7. Fujian Shengnong and OSI
    • 2.4.8. Shineway and Nippon Ham
    • 2.4.9. Avian Flu
  • 2.5. Dairy cattle
    • 2.5.1. Structural change
  • 2.6. Aquaculture
  • 2.7. Pets

Chapter 3: Overview of China's animal health market

  • 3.1. Global and Chinese animal health industries compared
    • 3.1.1. Sales by market segment
    • 3.1.2. Slowdown
    • 3.1.3. Growth forecasts
  • 3.2. China and international trade of animal health products
    • 3.2.1. Imports of veterinary biologicals
    • 3.2.2. Imports of veterinary medicines
    • 3.2.3. Import trends
  • 3.3. China's domestic animal health industry
    • 3.3.1. China's animal health enterprises
    • 3.3.2. Financial overview of China's animal health enterprises
    • 3.3.3. Size of enterprises in veterinary medicines and veterinary biologicals
  • 3.4. Veterinary biological firms
    • 3.4.1. Overview
    • 3.4.2. Enterprise size
    • 3.4.3. Production capacity and capacity utilization rates
    • 3.4.4. Numbers of new products registered, registration codes and usage
    • 3.4.5. Popular veterinary products, 2015
    • 3.4.6. Asset structure
    • 3.4.7. Human capital
    • 3.4.8. Overview of veterinary biological enterprises
    • 3.4.9. Different structures of veterinary biological enterprise' financial performance
  • 3.5. Industry concentration
    • 3.5.1. Industry concentration in poultry sector
    • 3.5.2. Industry concentration in swine sector
    • 3.5.3. Industry concentration in cattle sector
    • 3.5.4. Comparison of sales of veterinary biological enterprise according to size
  • 3.6. Research overview
    • 3.6.1. New veterinary biologicals
    • 3.6.2. Investment in research
    • 3.6.3. Workforce engaged in research
    • 3.6.4. Research methods
    • 3.6.5. Research investment focus
    • 3.6.6. Research investment methods
  • 3.7. Veterinary biological sales overview
    • 3.7.1. Market overview
    • 3.7.2. Sales of veterinary biologicals for poultry
    • 3.7.3. Sales of veterinary biologicals for swine
    • 3.7.4. Cattle, sheep veterinary biologicals

Chapter 4: Compulsory vaccines

  • 4.1. Market overview
    • 4.1.1. Compulsory poultry vaccines
    • 4.1.2. Compulsory swine vaccines
    • 4.1.3. Compulsory cattle and ruminant vaccines
  • 4.2. Other veterinary biologicals
    • 4.2.1. Overview
    • 4.2.2. Main non-compulsory vaccine product sales
  • 4.3. Veterinary medicines and traditional Chinese veterinary medicines
    • 4.3.1. Number of enterprises
    • 4.3.2. Structure of veterinary medicine enterprises

Chapter 5: Economic overview

  • 5.1. Veterinary medicine production value
  • 5.2. Sales of veterinary medicine
    • 5.2.1. Veterinary medicine enterprises' rate of return on assets
  • 5.3. Research overview
    • 5.3.1. Research results
    • 5.3.2. Research investment
    • 5.3.3. Researchers
  • 5.4. Veterinary API enterprises
    • 5.4.1. Production capacity and capacity utilization rates of veterinary APIs
    • 5.4.2. Economic overview
    • 5.4.3. API registrations and utilization
    • 5.4.4. Overview
    • 5.4.5. Main API products
    • Antibiotic veterinary APIs
    • 5.4.6. Sales overview
    • Overview
    • 5.4.7. Production and sales trends by API category
    • 5.4.8. Sales of main API products
  • 5.5. Industry concentration
    • 5.5.1. Overall industry concentration
    • 5.5.2. Enterprise categories by sales
    • 5.5.3. Veterinary medicines
    • 5.5.4. Production capacity and capacity utilization
    • 5.5.5. Economic overview
    • 5.5.6. Registered veterinary medicine products
    • 5.5.7. Main veterinary medicine products
    • 5.5.8. Overall concentration rate

Chapter 6: Chinese veterinary medicine

Chapter 7: Exports

  • 7.1. API exports

Chapter 8: Overview of top 13 Chinese market-listed animal health companies

  • 8.1.1. Overview of 2014
  • 8.1.2. Overview of 2015
  • 8.2. China Animal Husbandry Group
    • 8.2.1. Foreign partnerships
    • 8.2.2. Subsidiaries
    • 8.2.3. Analysis: SOEs at risk or retrenching?
  • 8.3. China Animal Husbandry Industry Corporation Ltd. (CAHIC)
    • 8.3.1. Veterinary sales
    • 8.3.2. Foreign cooperation
    • 8.3.3. Prospects
  • 8.4. Jinyu Bio-Technology Co. Ltd. (Jinyu Baoling Biological Pharmaceutical)
    • 8.4.1. Production facilities
    • 8.4.2. Foreign partnerships
    • 8.4.3. Research
    • 8.4.4. Veterinary sales
    • 8.4.5. Prospects
  • 8.5. Tianjin Ringpu Biotechnology Co. Ltd.
    • 8.5.1. Products, sales and regional focus
  • 8.6. Xinjiang Tecon Animal Husbandry Bio-Technologu Co., Ltd (TECON)
    • 8.6.1. Finances
  • 8.7. Guangdong Wens Dahuanong Biotechnology Co. Ltd.
    • 8.7.1. Finances
    • 8.7.2. Analysis: Wens Foodstuff Group takeover
  • 8.8. Shandong Lukang
    • 8.8.1. Finances
  • 8.9. Pulike Biological Engineering
    • 8.9.1. Finances
  • 8.10. Zhejiang Shenghua Biok Biology Co. Ltd. (Qingdao Yibang Bioengineering Co., Ltd)
    • 8.10.1. Finances
  • 8.11. Beijing Dabeinong Technology Group
  • 8.12. China Animal Healthcare Ltd.
    • 8.12.1. Controversy
  • 8.13. Other important market listed and non-listed Chinese animal health companies

Chapter 9: Top International animal health companies

  • 9.1. Zoetis
    • 9.1.1. Financials
    • 9.1.2. Prospects
    • 9.1.3. Key quotes
  • 9.2. Merck/MSD Animal Health
    • 9.2.1. Products
    • 9.2.2. Financials and performance
  • 9.3. Merial
    • 9.3.1. Poultry vaccine portfolio development
    • 9.3.2. Veterinary products for swine
    • 9.3.3. Companion animal products
    • 9.3.4. R&D
    • 9.3.5. Financials
    • 9.3.6. Prospects
  • 9.4. Elanco
    • 9.4.1. Relationship with China Animal Healthcare
  • 9.5. Bayer Animal Health China
    • 9.5.1. Products
    • 9.5.2. Performance
  • 9.6. Boehringer Ingelheim
    • 9.6.1. Products
    • 9.6.2. Financials
    • 9.6.3. Strategy
  • 9.7. IDEXX Laboratories
  • 9.8. Virbac
  • 9.9. Ceva Sante Animale
  • 9.10. Other foreign firms
Back to Top